Shenzhen Beike Biotechnology Co., Ltd. announced the successful treatment of two similar spinal cord injury patients using two different procedures that involved umbilical cord stem cells.

One method involved surgical transplantation of stem cells directly into the spinal cord, while the other patient received the stem cells without surgery. The announcement was made following a two-month rehabilitation and evaluation period by physicians in the patients’ native countries of the U.S.A. and Romania. Details can be found on the news website, https://www.stemcellschina.com.

Treatment of stroke patients and those with other neurological diseases with stem cells from human umbilical cords has become increasingly popular only recently. Today, these treatments are being taken forward by countries outside the United States, including China, as FDA approval takes longer.

Link [biz.yahoo.com/prnews/060628/phw021.html?.v=62]

For more details you may contact :
Dr. Sean Hu - Chairman
Beike Biotech Co., Ltd.
Shenzhen Hi-Tech Industrial Park
8613823501818
info@beikebiotech.com
https://www.beikebiotech.com